Cargando…

Effect of Inhibiting Tumor Angiogenesis After Embolization in the Treatment of HCC with Apatinib-Loaded p(N-Isopropyl-Acrylamide-co-Butyl Methyl Acrylate) Temperature-Sensitive Nanogel

BACKGROUND: Transcatheter arterial embolization (TAE) is widely used in hepatocellular carcinoma (HCC) therapy. Tumor hypoxia often correlates with the recurrence and metastasis of the tumor and is the critical factor limiting the treatment effect of TAE. PURPOSE: To investigate the underlying mecha...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Chen, Shi, Qin, Liu, Jiacheng, Huang, Songjiang, Yang, Chongtu, Xiong, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780989/
https://www.ncbi.nlm.nih.gov/pubmed/33409168
http://dx.doi.org/10.2147/JHC.S282209
_version_ 1783631601409720320
author Zhou, Chen
Shi, Qin
Liu, Jiacheng
Huang, Songjiang
Yang, Chongtu
Xiong, Bin
author_facet Zhou, Chen
Shi, Qin
Liu, Jiacheng
Huang, Songjiang
Yang, Chongtu
Xiong, Bin
author_sort Zhou, Chen
collection PubMed
description BACKGROUND: Transcatheter arterial embolization (TAE) is widely used in hepatocellular carcinoma (HCC) therapy. Tumor hypoxia often correlates with the recurrence and metastasis of the tumor and is the critical factor limiting the treatment effect of TAE. PURPOSE: To investigate the underlying mechanism and therapeutic potential of TAE combined with apatinib-loaded p(N-isopropyl-acrylamide-co-butyl methyl acrylate) temperature-sensitive (PIB) nanogel for the suppression of rabbit VX2 liver tumor growth. MATERIALS AND METHODS: Sixty-five VX2 tumor-burdened rabbits were randomly divided into five groups and treated transarterially with apatinib-loaded PIB (Group PA, 0.4 mL, n=13), PIB alone (Group P, 0.4 mL, n=13), iodized oil alone (Group I, 0.4 mL, n=13), apatinib solution (Group A, 0.4 mL, n=13) or saline (Group NS, 0.4 mL, n=13). The dose of apatinib was 2 mg/kg. Tumors were harvested, sectioned and immunohistochemically stained, and the tumor growth rates and survival times in each group were measured. Blood samples and liver tissues were collected for pharmacokinetic analysis. RESULTS: The tumor growth rate in Group PA was considerably lower than the other four groups (P=0.000<0.01), and the survival time was significantly prolonged (P=0.000<0.01). The immunohistochemistry results showed that CD31 expression was significantly lower in Group PA than that of the other four groups (P=0.000<0.01). The apatinib concentration in the blood fell below 10 ng/mL within 10 min after TAE and dropped below 1 ng/mL after 8 h. The drug was released continuously in the liver for 36 days, with the highest concentration at the tumor junction (P=0.045<0.05). CONCLUSION: PIB effectively targeted apatinib to HCC tissues, achieved a slow and sustained release of the drug in the tumor and considerably reduced the systemic drug concentration. Further experiments showed significantly prolonged survival times and an inhibitory effect on tumor growth.
format Online
Article
Text
id pubmed-7780989
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-77809892021-01-05 Effect of Inhibiting Tumor Angiogenesis After Embolization in the Treatment of HCC with Apatinib-Loaded p(N-Isopropyl-Acrylamide-co-Butyl Methyl Acrylate) Temperature-Sensitive Nanogel Zhou, Chen Shi, Qin Liu, Jiacheng Huang, Songjiang Yang, Chongtu Xiong, Bin J Hepatocell Carcinoma Original Research BACKGROUND: Transcatheter arterial embolization (TAE) is widely used in hepatocellular carcinoma (HCC) therapy. Tumor hypoxia often correlates with the recurrence and metastasis of the tumor and is the critical factor limiting the treatment effect of TAE. PURPOSE: To investigate the underlying mechanism and therapeutic potential of TAE combined with apatinib-loaded p(N-isopropyl-acrylamide-co-butyl methyl acrylate) temperature-sensitive (PIB) nanogel for the suppression of rabbit VX2 liver tumor growth. MATERIALS AND METHODS: Sixty-five VX2 tumor-burdened rabbits were randomly divided into five groups and treated transarterially with apatinib-loaded PIB (Group PA, 0.4 mL, n=13), PIB alone (Group P, 0.4 mL, n=13), iodized oil alone (Group I, 0.4 mL, n=13), apatinib solution (Group A, 0.4 mL, n=13) or saline (Group NS, 0.4 mL, n=13). The dose of apatinib was 2 mg/kg. Tumors were harvested, sectioned and immunohistochemically stained, and the tumor growth rates and survival times in each group were measured. Blood samples and liver tissues were collected for pharmacokinetic analysis. RESULTS: The tumor growth rate in Group PA was considerably lower than the other four groups (P=0.000<0.01), and the survival time was significantly prolonged (P=0.000<0.01). The immunohistochemistry results showed that CD31 expression was significantly lower in Group PA than that of the other four groups (P=0.000<0.01). The apatinib concentration in the blood fell below 10 ng/mL within 10 min after TAE and dropped below 1 ng/mL after 8 h. The drug was released continuously in the liver for 36 days, with the highest concentration at the tumor junction (P=0.045<0.05). CONCLUSION: PIB effectively targeted apatinib to HCC tissues, achieved a slow and sustained release of the drug in the tumor and considerably reduced the systemic drug concentration. Further experiments showed significantly prolonged survival times and an inhibitory effect on tumor growth. Dove 2020-12-31 /pmc/articles/PMC7780989/ /pubmed/33409168 http://dx.doi.org/10.2147/JHC.S282209 Text en © 2020 Zhou et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Zhou, Chen
Shi, Qin
Liu, Jiacheng
Huang, Songjiang
Yang, Chongtu
Xiong, Bin
Effect of Inhibiting Tumor Angiogenesis After Embolization in the Treatment of HCC with Apatinib-Loaded p(N-Isopropyl-Acrylamide-co-Butyl Methyl Acrylate) Temperature-Sensitive Nanogel
title Effect of Inhibiting Tumor Angiogenesis After Embolization in the Treatment of HCC with Apatinib-Loaded p(N-Isopropyl-Acrylamide-co-Butyl Methyl Acrylate) Temperature-Sensitive Nanogel
title_full Effect of Inhibiting Tumor Angiogenesis After Embolization in the Treatment of HCC with Apatinib-Loaded p(N-Isopropyl-Acrylamide-co-Butyl Methyl Acrylate) Temperature-Sensitive Nanogel
title_fullStr Effect of Inhibiting Tumor Angiogenesis After Embolization in the Treatment of HCC with Apatinib-Loaded p(N-Isopropyl-Acrylamide-co-Butyl Methyl Acrylate) Temperature-Sensitive Nanogel
title_full_unstemmed Effect of Inhibiting Tumor Angiogenesis After Embolization in the Treatment of HCC with Apatinib-Loaded p(N-Isopropyl-Acrylamide-co-Butyl Methyl Acrylate) Temperature-Sensitive Nanogel
title_short Effect of Inhibiting Tumor Angiogenesis After Embolization in the Treatment of HCC with Apatinib-Loaded p(N-Isopropyl-Acrylamide-co-Butyl Methyl Acrylate) Temperature-Sensitive Nanogel
title_sort effect of inhibiting tumor angiogenesis after embolization in the treatment of hcc with apatinib-loaded p(n-isopropyl-acrylamide-co-butyl methyl acrylate) temperature-sensitive nanogel
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780989/
https://www.ncbi.nlm.nih.gov/pubmed/33409168
http://dx.doi.org/10.2147/JHC.S282209
work_keys_str_mv AT zhouchen effectofinhibitingtumorangiogenesisafterembolizationinthetreatmentofhccwithapatinibloadedpnisopropylacrylamidecobutylmethylacrylatetemperaturesensitivenanogel
AT shiqin effectofinhibitingtumorangiogenesisafterembolizationinthetreatmentofhccwithapatinibloadedpnisopropylacrylamidecobutylmethylacrylatetemperaturesensitivenanogel
AT liujiacheng effectofinhibitingtumorangiogenesisafterembolizationinthetreatmentofhccwithapatinibloadedpnisopropylacrylamidecobutylmethylacrylatetemperaturesensitivenanogel
AT huangsongjiang effectofinhibitingtumorangiogenesisafterembolizationinthetreatmentofhccwithapatinibloadedpnisopropylacrylamidecobutylmethylacrylatetemperaturesensitivenanogel
AT yangchongtu effectofinhibitingtumorangiogenesisafterembolizationinthetreatmentofhccwithapatinibloadedpnisopropylacrylamidecobutylmethylacrylatetemperaturesensitivenanogel
AT xiongbin effectofinhibitingtumorangiogenesisafterembolizationinthetreatmentofhccwithapatinibloadedpnisopropylacrylamidecobutylmethylacrylatetemperaturesensitivenanogel